All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Reported results | 2004-000404-40 | A double blind, randomised, placebo-controlled study to investigate chronic intermittent ''pulse'' therapy of moxifloxacin as a prevention of acute exacerbation in out-patients with chronic bronchitis | 2007-01-10 | due-trials |
| Reported results | 2004-000725-30 | A phase II, multi-centre, open-label, uncontrolled study to evaluate the efficacy and safety of BAY 43-9006 given daily in combination with repeated 21-day cycles of dacarbazine (DTIC) chemotherapy in... | 2008-06-13 | due-trials |
| Reported results | 2004-001083-43 | Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with acute symptomatic Deep Vein Thrombosis ODIXa-DVT A prospective, randomized, multinational, multicenter, partially blinded, parallel-group, ... | 2005-10-05 | due-trials |
| Reported results | 2004-001341-14 | Controlled, Double-Blind, Randomized, Dose-ranging Study of once-daily regimen of BAY59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement-ODIXa-OD.HIP Study | 2005-07-27 | due-trials |
| Reported results | 2004-001770-40 | A randomized controlled study of BAY 43-9006 in combination with doxorubicin versus doxorubicin in patients with advanced hepatocellular carcinoma. | 2008-04-11 | due-trials |
| Reported results | 2004-001773-26 | A Phase III randomised, placebo-controlled study of sorafenib in patients with advanced hepatocellular carcinoma | 2008-11-21 | due-trials |
| Reported results | 2004-002171-16 | Once-daily oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with acute symptomatic Deep Vein Thrombosis. The Einstein-DVT dose-finding study. | 2005-12-07 | due-trials |
| Reported results | 2004-002172-42 | A randomized, double-blind, double-dummy, multi-center, parallel group study to compare the tolerability and efficacy of once daily vardenafil versus vardenafil PRN versus placebo in men immediately a... | 2007-12-17 | due-trials |
| Reported results | 2004-002291-42 | Multi-center, open, randomized, dose finding phase II study to investigate for a maximum of three years ultra low dose levonorgestrel contraceptive intrauterine systems (LCS) releasing in vitro 12 µg/... | 2008-12-09 | due-trials |
| Reported results | 2004-005079-40 | Placebo and active controlled, double dummy phase II study to prove efficacy of Aspirin (1000 mg solid dose) in treatment of acute low back pain. | 2006-12-19 | due-trials |
| Reported results | 2004-005282-37 | Double-blind, cross-over, placebo-controlled pilot study to characterize the profile of those patients with traumatic spinal cord injury diagnosed by electrophysiological, urodynamic and clinical (ASI... | 2007-02-13 | due-trials |
| Reported results | 2005-000544-86 | A randomised, open-label, multi-center phase II study of first-line treatment with BAY 43-9006 (Sorafenib) versus standard treatment with Interferon alpha-2a in patients with unresectable and/or metas... | 2010-06-23 | due-trials |
| Reported results Terminated | 2005-000586-19 | Phase-II study to investigate the efficacy and safety of ZK 219477 as second-line therapy in patients with Stage IIIB or Stage IV non-small-cell lung cancer (NSCLC) | 2009-04-15 | due-trials |
| Reported results | 2005-001678-28 | A randomized, explorative, double-blind, double-dummy, multi-center, parallel group study to assess sustainable efficacy of once daily vardenafil (10 mg) for 12 and 24 weeks versus vardenafil PRN in m... | 2007-03-20 | due-trials |
| Reported results | 2005-001720-36 | A pivotal, placebo controlled, phaseIII study to compare efficacy and tollerability of a fixed combination, containing 500 mg ASA and 30 mg Pseudoephedrine, in comparison to its single components in p... | 2007-05-14 | due-trials |
| Reported results | 2005-001727-11 | A phase III, open-label, prospective, two armed multicenter, randomized, group sequential study to evaluate the efficacy and safety of subsequent treatment with the Zevalin (ibritumomab tiuxetan) stud... | 2008-12-05 | due-trials |
| Reported results | 2005-002125-32 | A multicenter, open, randomized, parallel-group comparison to assess the safety and efficacy of the oral contraceptive SH T 00186 D (0.02 mg ethinylestradiol as betadex clathrate and 3 mg drospirenone... | 2008-10-28 | due-trials |
| Reported results | 2005-002524-34 | An Open Label, Non Comparative, Phase III Study of the Raf Kinase Inhibitor BAY 43-9006 as a Subsequent to First Line Therapy in Patients with Advanced Renal Cell Carcinoma | 2008-11-05 | due-trials |
| Reported results | 2005-002757-45 | A prospective controlled study on the effect on bleeding events and joint function in young adults with severe hemophilia A after a 6 month prophylaxis treatment compared to on demand treatment | 2008-03-25 | due-trials |
| Completed, but no date, and reported results Terminated | 2005-002779-34 | Prospective, multicenter, randomized, double blind, parallel arm study to evaluate the efficacy and safety of Moxifloxacin 400 mg OD for 7 days versus amoxicillin clavulanate/claritromycin for 10 days... | bad-data | |
| Reported results | 2005-002796-32 | A randomized, double-blind, placebo-controlled, multi-center, parallel group study to assess the efficacy of vardenafil in the treatment of symtomatic Benign Prostatic Hyperplasia | 2006-06-19 | due-trials |
| Reported results | 2005-003216-30 | Ensayo clínico de fase II prospectivo, multicéntrico, aleatorizado de grupos paralelos, abierto, para estudiar la eficacia, seguridad y tolerabilidad de 2 dosis de ZK 219477 (16 y 12 mg/m2 de área de ... | 2009-01-15 | due-trials |
| Reported results | 2005-003999-38 | A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, 2-Arm Study to Investigate the Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Elective Spinal Fus... | 2007-01-25 | due-trials |
| Reported results | 2005-004055-35 | A multi-center, randomized, double blind, placebo controlled study to investigate the efficacy and safety of Aprotinin on transfusion requirements in patients with bladder cancer undergoing radical or... | 2007-01-25 | due-trials |
| Reported results | 2005-004340-32 | A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, 7 Cycle Duration (196 Days), Phase 3 Study of Oral Estradiol Valerate/Dienogest Tablets for the Treatment of Dysfunctional ... | 2008-05-27 | due-trials |
| Reported results | 2005-004351-35 | Ensayo clínico controlado, doble ciego y aleatorizado de BAY 59-7939 en la prevención del tromboembolismo venoso en pacientes con cirugía electiva de sustitución total de cadera. Estudio RECORD 1 REC... | 2007-03-13 | due-trials |
| Reported results | 2005-004473-14 | Proof of concept study to investigate the impact of BAY 58-2667 given intravenously in patients with acute decompensated chronic congestive heart failure | 2007-05-21 | due-trials |
| Reported results | 2005-004620-40 | Ensayo clínico controlado, doble ciego y aleatorizado de BAY 59-7939 en la prevención del tromboembolismo venoso en sujetos con cirugía electiva de sustitución total de rodilla. Estudio RECORD 3 RECO... | 2007-04-20 | due-trials |
| Reported results Terminated | 2005-004689-18 | A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, 2-Arm Study to Investigate the Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Surgical Procedures... | 2007-03-13 | due-trials |
| Reported results | 2005-004691-20 | RECORD 2 Study: REgulation of Coagulation in ORthopedic Surgery to prevent DVT and PE, controlled, Double-Blind, Randomized Study of BAY59-7939 in the Extended Prevention of VTE in Patients Undergoing... | 2007-05-07 | due-trials |
| Reported results | 2005-005245-19 | A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel plus or minus Sorafenib BAY 43-9006 in chemonaive patients with Stage IIIB-IV Non-Small Cell Lung Cancer NS... | 2009-02-05 | due-trials |
| Reported results | 2005-005581-36 | Estudio fase II aleatorizado para investigar la eficacia, seguridad y tolerabilidad de ZK 230211 (100 mg frente a 25 mg) como tratamiento endocrino de segunda línea en mujeres posmenopáusicas con cánc... | 2011-03-21 | due-trials |
| Exempt, with results | 2006-000067-29 | Phase I/II study to investigate the safety, tolerability, efficacy and pharmacokinetics of ZK 219477 in combination with cisplatin as first-line therapy in chemotherapy-naive patients with extensive-d... | 2009-08-17 | not-yet-due |
| Reported results | 2006-000394-30 | Multicenter study to investigate the bleeding profile and the insertion easiness in women inserted with a second consecutive MIRENA for contraception or menorrhagia | 2012-10-18 | due-trials |
| Reported results | 2006-000463-29 | Evaluation of vardenafil for the treatment of subjective tinnitus: A controlled pilot study | 2007-09-06 | due-trials |
| Reported results | 2006-000874-56 | A prospective, randomized, double dummy, double blind, multi-center trial comparing the safety and efficacy of moxifloxacin 400 mg IV QD 24 hours to that of ertapenem 1.0 g IV QD 24 hours for 5 to 14 ... | 2009-03-25 | due-trials |
| Reported results | 2006-001228-37 | A randomized, double blind, parallel group study of vardenafil flexible dose versus placebo in males with erectile dysfunction and their female partners’ sexual quality of life. PARTNER II | 2007-08-03 | due-trials |
| Reported results | 2006-001599-18 | A prospective, randomized, double dummy, double blind, multinational, multicenter trial comparing the safety and efficacy of sequential intravenous/oral moxifloxacin 400 mg once daily to intravenous... | 2018-06-12 | due-trials |
| Reported results Terminated | 2006-002361-39 | A 4-week, open-label, multicenter, urodynamic pilot study to explore the efficacy, tolerability and safety of darifenacin (7.5 mg with up-titration to 15 mg) in patients with multiple sclerosis and ne... | 2007-09-21 | due-trials |
| Reported results | 2006-002402-60 | RECORD 4 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE; a controlled, double-blind, randomized study of BAY 59-7939 in the prevention of VTE in subjects undergoing elect... | 2008-05-14 | due-trials |
| Reported results | 2006-002688-26 | A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients ... | 2011-06-14 | due-trials |
| Exempt, with results | 2006-003520-10 | A multicenter, non-randomized, non-blinded, non-controlled study to investigate the impact of multiple doses of BAY 63 2521 on safety, tolerability, pharmacokinetics, and pharmacodynamics in patients ... | 2014-09-12 | not-yet-due |
| Reported results | 2006-003622-29 | Estudio ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events, aspirina para reducir el riesgo de accidentes vasculares iniciales) – Estudio aleatorizado, doble ciego, controlado con placebo, mult... | 2017-11-15 | due-trials |
| Exempt, with results | 2006-004153-22 | Open-label multi-center study of magnetic resonance imaging (MRI) with 0.1 mmol/kg BW Gadovist (1.0 M) to assess pharmacokinetics, safety and tolerability in children | 2008-06-04 | not-yet-due |
| Reported results | 2006-004397-27 | Multi-center, double-blind, placebo-controlled study to investigate the efficacy and safety of daily oral 100 mg dehydroepiandrosterone (DHEA) over 6 treatment cycles as a concomitant therapy to oral ... | 2009-04-22 | due-trials |
| Reported results | 2006-004449-40 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation and Dose-Confirmation Study to Evaluate the Safety and Efficacy of Rivaroxaban in Combination with Aspirin Alone or with As... | 2008-10-22 | due-trials |
| Reported results | 2006-004458-26 | Randomized, comparative, open label treatment with double-blind placebo-controlled periods within treatment study to evaluate the efficacy and safety of a once-a-week prophylaxis treatment with BAY 79... | 2007-06-15 | due-trials |
| Reported results | 2006-004494-96 | Once-daily oral direct factor Xa inhibitor rivaroxaban in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary emboli... | 2009-09-17 | due-trials |
| Reported results | 2006-004495-13 | Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. | 2011-12-01 | due-trials |
| Reported results | 2006-004595-13 | A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) w... | 2010-10-08 | due-trials |
| Reported results | 2006-004633-15 | A randomized, double-blind, parallel group prospective pilot study to assess the effect of vardenafil on clinical outcome and on procedure duration after green light laser-ablation of the prostate gla... | 2009-04-24 | due-trials |
| Reported results | 2006-004899-13 | A multi-center, open-label, randomized, controlled, parallel-group study to assess efficacy and safety of an extended flexible regimen of the combined oral contraceptive SH T00186D (0.02 mg ethinylest... | 2009-12-01 | due-trials |
| Reported results | 2006-005145-11 | Estudio aleatorizado, doble ciego, controlado con placebo, de grupos paralelos con una dosis de 10 mg de vardenafilo dos veces al día para evaluar el efecto en la prueba urodinámica en pacientes con v... | 2008-11-13 | due-trials |
| Reported results | 2006-005270-47 | Estudio internacional, multicéntrico, de fase IIIb, sobre el tratamiento en días alternos de pacientes con Esclerosis Múltiple Recidivante con: (Fase A) Betaseron/Betaferon 250 µg ó 500 µg de forma do... | 2008-06-17 | due-trials |
| Reported results | 2006-005508-14 | A randomized, , double-blind, single centre, intra-individual comparison study with repeated application to assess the wound-healing efficacy of a 5 % Dexpanthenol ointment compared with placebo in pa... | 2007-04-23 | due-trials |
| Reported results | 2006-006199-39 | A double-blind, randomized, multi-center study to investigate the endometrial safety of a continuous, combined, oral estrogen/progestin preparation (0.5 mg 17β-estradiol [E2] / 0.25 mg drospire... | 2009-08-17 | due-trials |
| Reported results | 2006-006436-22 | A multicenter Study Evaluating the Efficacy of Nifedipine GITS ﾖ Telmisartan Combination in Blood Pressure Control and Beyond: comparison of two strategies. | 2009-11-06 | due-trials |
| Reported results | 2006-006633-41 | Monocenter, open-label, randomized study to determine the ovulation inhibitory effect of the combined oral contraceptives SH T04769G (0.015 mg Ethinylestradiol and 1.5 mg Dienogest in a modified relea... | 2008-06-03 | due-trials |
| Reported results | 2006-006673-24 | Etude pilote multicentrique de phase IV, en ouvert, randomisée, en groupe parallèles destinée à évaluer l'éfficacité d'un protocole de rééducation fonctionnelle des patients atteints d'une forme récur... | 2009-09-24 | due-trials |
| Reported results | 2007-000072-16 | Ensayo clínico, multinacional, multicéntrico, aleatorizado ,doble ciego, controlado con placebo, para evaluar la eficacia y la seguridad de BAY 63-2521 (1 mg, 1.5 mg, 2mg, o 2.5 mg,tid), administrado ... | 2012-07-27 | due-trials |
| Reported results | 2007-000420-40 | Multi-center, open-label, randomized study to assess the safety and contraceptive efficacy of two doses (in vitro 12 µg/24 h and 16 µg/24 h) of the ultra low dose levonorgestrel contraceptive intraute... | 2013-06-03 | due-trials |
| Reported results | 2007-000425-22 | Phase IIa Efficacy and Safety Trial of capadenoson in Patients with Chronic Stable Angina | 2008-03-20 | due-trials |
| Reported results | 2007-000583-25 | A randomized, double masked, active controlled, phase 3 study of the efficacy, safety, and tolerability of repeated doses of intravitreal VEGF Trap-Eye in subjects with neovascular age-related macular... | 2011-08-11 | due-trials |
| Completed, but no date, and reported results Terminated | 2007-001320-12 | A national, prospective, randomized, open label study to asses the efficacy and safety of IV/PO moxifloxacin vs IV ceftriaxone + IV azithromicin followed by PO amoxicilline/clavulanate and PO claritr... | bad-data | |
| Completed, but no date, and reported results Terminated | 2007-001491-36 | ''A prospective, randomized, open label, active comparator, multicenter, national trial to compare the efficacy and safety of sequential IV/PO moxifloxacin 400 mg once daily versus IV amoxicillin/clav... | bad-data | |
| Reported results | 2007-001791-36 | A double-blind, randomized, placebo and active controlled, multicenter study to investigate efficacy and safety after oral administration of 2 and 3 mg ZK 283197, 1 mg 17ß-estradiol and placebo once d... | 2009-02-11 | due-trials |
| Reported results | 2007-002256-42 | An open-label, non-randomized, multi-center study to optimize image assessment and evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) for detection/exclusi... | 2010-11-30 | due-trials |
| Reported results | 2007-002365-13 | Sorafenib as adjuvant to radioiodine therapy in non-medullary thyroid carcinoma | 2008-12-10 | due-trials |
| Reported results | 2007-002604-17 | Programa de extensión a largo plazo con sorafenib Sorafenib Long Term Extension Program (STEP) | 2021-09-24 | due-trials |
| Exempt, with results | 2007-002912-24 | Study to evaluate the safety and pharmacokinetics of ciprofloxacin following inhalation of ciprofloxacin dry powder for inhalation administered to pediatric patients with cystic fibrosis aged 12-17 ye... | 2008-07-07 | not-yet-due |
| Reported results Terminated | 2007-003059-36 | Estudio aleatorizado, doble ciego, controlado con placebo, multicéntrico y multinacional de fase IIb para evaluar la eficacia y la tolerabilidad de BAY 58 2667 administrado por vía intravenosa en paci... | 2009-03-26 | due-trials |
| Reported results | 2007-003619-30 | Study to investigate the effect of the A1 agonist capadenoson on ventricular HR in patients with persistent or permanent atrial fibrillation by administration of capadenoson in a dose of 4 mg once dai... | 2009-03-05 | due-trials |
| Reported results | 2007-003718-32 | Ensayo clínico, controlado , doble ciego, paralelo, para evaluar la eficacia y seguridad del tratamiento profiláctico con BAY 79-4980 administrado una vez por semana, comparado con el tratamiento con ... | 2010-10-05 | due-trials |
| Ongoing | 2007-003928-37 | A multicenter, non-randomized, non-blinded, non-controlled study to investigate the impact of multiple doses of BAY 63-2521 on safety, tolerability, pharmacokinetics and pharmacodynamics in patients w... | not-yet-due | |
| Reported results | 2007-004544-73 | A double-blind, randomized, uncontrolled study to evaluate inhibition of ovulation of two oral estradiol / drospirenone regimens in healthy young female volunteers over a period of 3 treatment cycles | 2009-01-26 | due-trials |
| Reported results | 2007-004614-14 | MAGELLAN - Estudio Multicéntrico, Aleatorizado, de Grupos paralelos, para evaluar la superioridad de la Eficacia de rivaroxabAN frente enoxaparina en la profilaxis de sujetos médicos hospitalizados. | 2010-11-24 | due-trials |
| Reported results | 2007-004746-33 | A multicenter, randomized, double-blind, crossover, phase 3 study to determine the safety and efficacy of gadobutrol 1.0 molar (Gadovist®) in patients referred for contrast-enhanced MRI of the central... | 2009-04-05 | due-trials |
| Reported results | 2007-004875-21 | A Phase II, Multi-centre, Open-label Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Intrapatient Dose Escalation of Sorafenib as First Line Treatment for Metastatic Renal C... | 2011-01-13 | due-trials |
| Reported results | 2007-005083-28 | A Phase II, Randomized, Open-label, MultiCenter, Study Evaluating the Efficacy of SOrafenib AloNe and Sorafenib in Combination with Low DosE InterfeRon Alpha-2a as Second-line Treatment of Sunitinib F... | 2009-06-26 | due-trials |
| Reported results | 2007-005163-94 | A prospective, randomized, verum controlled, open label, parallel group multi-center phase III clinical trial to demonstrate the superiority of 500 or 250 mg Aspirin® i.v. (BAY 81-8781) treatment vers... | 2014-06-03 | due-trials |
| Reported results | 2007-005258-22 | A multi-center, double-blind, randomized, parallel-group study to evaluate cycle control and safety of 6 different regimens of an oral contraceptive containing estradiol and drospirenone in healthy fe... | 2009-07-23 | due-trials |
| Reported results | 2007-005693-31 | Contrast-enhanced MRI examination of cerebral neoplastic enhancing lesions: comparison of diagnostic efficacy of Gd-DOTA 0.5 M and gadobutrol 1.0 M at 0.1 mmol Gd/kg body weight: Intra-individual com... | 2009-05-05 | due-trials |
| Reported results | 2007-006096-37 | A prospective, multinational, multicenter, randomized, double blind, double dummy, controlled study comparing the efficacy and safety of moxifloxacin to that of amoxicillin clavulanic acid for the tre... | 2011-03-04 | due-trials |
| Reported results | 2008-000107-28 | A Phase II uncontrolled study of BAY 73-4506 (DAST) in previously untreated patients with metastatic or unresectable renal cell cancer (RCC) | 2019-04-07 | due-trials |
| Reported results | 2008-000536-40 | Ensayo pivotal de fase III para determinar la eficacia y la seguridad del comprimido bucodispersable de vardenafilo comparado con placebo en el tratamiento de hombres con disfunción eréctil (DE) – ens... | 2009-01-19 | due-trials |
| Reported results | 2008-000583-16 | Multi-center, randomized comparison study to eVALUatE outcomes and resource needs of imaging and treatment following Primovist-enhanced MRI of the liver in comparison to extra-cellular con... | 2010-12-31 | due-trials |
| Reported results | 2008-000718-63 | An investigator-blinded, active-controlled phase 3 study to prove the non-inferior efficacy of a Clotrimazole ovule (500 mg) versus a Clotrimazole vaginal tablet (500 mg) in vaginal candidiasis | 2009-06-29 | due-trials |
| Reported results | 2008-000879-26 | (REASON) double-blind, Randomized phase II study to Evaluate the safety and efficacy of Acetyl-l-carnitine in the prevention of SagOpilone-induced peripheral Neuropathy. | 2010-08-05 | due-trials |
| Reported results | 2008-000906-35 | A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Patient... | 2017-11-10 | due-trials |
| Reported results | 2008-000985-21 | Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared... | 2013-11-22 | due-trials |
| Reported results | 2008-001087-36 | A Phase III randomized, double-blind, placebo-controlled study of sorafenib as adjuvant treatment for hepatocellular carcinoma after surgical resection or local ablation. | 2014-11-28 | due-trials |
| Reported results Terminated | 2008-001198-13 | Multicenter, open-label, randomized, uncontrolled study to evaluate inhibition of ovulation of two transdermal patch formulations containing 0.55 mg ethinylestradiol and either 1.05 or 2.1 mg gestoden... | 2009-02-19 | due-trials |
| Reported results Terminated | 2008-001494-15 | Phase I/II Study of Sagopilone in combination with carboplatin and bevacizumab in the first-line treatment of patients with stage IIIB/IV, non-squamous NSCLC. | 2008-12-04 | due-trials |
| Reported results Terminated | 2008-002053-20 | A 54 week treatment, randomized, multi center, double blind, placebo controlled study to assess the safety and efficacy of NEBIDO 1000 mg (4 ml) in elderly men with symptomatic late onset hypogonadism... | 2008-10-13 | due-trials |
| Reported results | 2008-002069-30 | A randomized, double-blind, single centre, placebo-controlled pilot study to assess on a molecular level the influence of a 5 % dexpanthenol ointment in subjects with previously injured skin by invest... | 2009-02-27 | due-trials |
| Reported results | 2008-002140-41 | Double-blind, placebo controlled, randomized study of vardenafil to determine efficacy on Erectile Dysfunction (ED) in men with ED and Metabolic Syndrome ("ED-METABOLIC") | 2009-10-08 | due-trials |
| Reported results | 2008-002263-13 | Multi-center, double-blind, randomized study to investigate the impact of a sequential oral contraceptive containing estradiol valerate and dienogest (SH T00658ID) compared to a monophasic contracepti... | 2010-07-20 | due-trials |
| Reported results | 2008-003215-13 | A double-blind, randomized, multicenter, placebo-controlled phase 3 trial to prove the superiority of bifonazole vs. placebo after 4 weeks of onychomycosis treatment (as a follow-up of a 2 weeks treat... | 2010-01-21 | due-trials |
| Reported results | 2008-003226-42 | A multicenter, randomized, double-blind, active-controlled, parallel group, 2-arm study to investigate the effect of estradiol valerate/dienogest compared to Microgynon on hormone withdrawal associate... | 2010-12-28 | due-trials |
| Reported results | 2008-003303-31 | The Einstein CYP cohort study. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism using a strong CYP 3A4 inducer | 2011-06-26 | due-trials |
| Reported results | 2008-003482-68 | Ensayo clínico, multinacional, multicéntrico, aleatorizado ,doble ciego, controlado con placebo, para evaluar la eficacia y la seguridad de BAY 63-2521 (1 mg, 1.5 mg, 2mg, o 2.5 mg ,tid )administrado ... | 2012-05-14 | due-trials |
| Reported results | 2008-003539-19 | Estudio de extensión a largo plazo, multicéntrico y multinacional, para evaluar la seguridad y tolerabilidad de BAY 63 2521 (1 mg, 1,5 mg, 2 mg o 2,5 mg tid) administrado por vía oral, en pacientes co... | 2019-08-19 | due-trials |
| Reported results | 2008-003610-94 | Estudio de extensión a largo plazo, multicéntrico y multinacional, para evaluar la seguridad y tolerabilidad de BAY 63 2521 (1 mg, 1,5 mg, 2 mg o 2,5 mg tid) administrado por vía oral, en pacientes co... | 2019-08-19 | due-trials |
| Reported results | 2008-004214-27 | Estudio multicéntrico, abierto, no controlado para investigar la eficacia y seguridad del parche anticonceptivo transdérmico que contiene 0,55 mg de etinilestradiol y 2,1 mg de gestodeno (n.º de mater... | 2011-09-21 | due-trials |
| Reported results | 2008-004429-41 | A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients who have achieved a Com... | 2012-12-12 | due-trials |
| Reported results | 2008-004496-22 | Prospective non-randomized (pharmacoepidemiologic) cohort study (open-label, multicenter) to assess the magnitude of potential risk with the administration of Gadovist® in patients with moderate to se... | 2015-05-28 | due-trials |
| Reported results | 2008-005025-11 | A Phase 2b, Double Blind, Randomized Study Evaluating the Efficacy and Safety of Sorafenib Compared With Placebo When Administered in Combination With Chemotherapy (Modified FOLFOX6) for the Treatment... | 2012-02-15 | due-trials |
| Reported results | 2008-005056-24 | A Phase II randomized, double-blind, placebo-controlled study of sorafenib or placebo in combination with transarterial chemoembolisation (TACE) performed with DC Bead and doxorubicin for intermediate... | 2013-02-08 | due-trials |
| Reported results | 2008-005625-11 | A multi-center, double-blind, double-dummy, randomized, controlled, parallel-group study to assess efficacy and safety of SH T00658ID compared to SH D593B in the treatment of primary dysmenorrhea | 2010-11-18 | due-trials |
| Reported results | 2008-005654-21 | An investigator-blind, randomized, multicenter, 5-arm, placebo- and active controlled parallel group pilot trial to explore the efficacy and tolerability of topical bifonazole liquid spray in patients... | 2010-05-26 | due-trials |
| Reported results | 2008-005867-33 | Prospective non-randomized (pharmacoepidemiologic) cohort study (open-label, multicenter) to assess the magnitude of potential risk with the administration of Primovist/Eovist in patients with moderat... | 2013-07-24 | due-trials |
| Reported results | 2008-006021-14 | A Phase III randomized, placebo controlled, double blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC) | 2018-05-23 | due-trials |
| Reported results Terminated | 2008-006022-34 | Randomized phase II study of sorafenib plus bicaluamide vs. placebo plus bicalutamide in castration-resistant asymptomatic or mildly symptomatic metastatic prostate cancer patients who had orchiectomy... | 2008-12-19 | due-trials |
| Reported results | 2008-006914-62 | A Phase III, multi-center, placebo controlled trial of Sorafenib (BAY 43-9006) in patients with relapsed or refractory advanced predominantly non squamous Non-Small Cell Lung Cancer (NSCLC) after 2 or... | 2013-04-02 | due-trials |
| Reported results | 2008-007024-26 | A single-center, open-label, crossover, randomized study to investigate the impact of the transdermal contraceptive patch containing 0.55 mg ethinylestradiol and 2.1 mg gestogene (material no. 8087639... | 2011-05-09 | due-trials |
| Reported results | 2008-007308-27 | Multi-center, open-label, randomized, parallel-group comparison of cycle control, bleeding pattern, lipid and carbohydrate metabolism of the transdermal contraceptive patch containing 0.55 mg ethinyle... | 2010-09-03 | due-trials |
| Reported results | 2008-008314-40 | Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of inhaled ciprofloxacin compared to placebo in subjects with cystic fibrosis | 2011-01-26 | due-trials |
| Reported results | 2009-009177-10 | Multicenter, open-label, randomized study to evaluate inhibition of ovulation of two transdermal patch formulations containing 0.55 mg ethinylestradiol and either 1.05 or 2.1 mg gestodene in healthy y... | 2011-08-23 | due-trials |
| Reported results | 2009-009597-27 | An open label, multi-center, phase 3 study with corresponding blinded image reading to determine the efficacy and safety of a single intravenous injection of 0.1 mmol/kg body weight of gadobutrol 1.0 ... | 2012-03-16 | due-trials |
| Reported results | 2009-009598-90 | An open label, multi-center, phase 3 study with corresponding blinded image reading to determine the efficacy and safety of a single intravenous injection of 0.1 mmol/kg body weight of gadobutrol 1.0 ... | 2013-09-28 | due-trials |
| Reported results | 2009-009869-34 | Randomized, placebo-controlled, double-blind, multi center study to evaluate the safety and efficacy of ciprofloxacin inhale compared to placebo in patients with non-cystic fibrosis bronchiectasis | 2010-09-17 | due-trials |
| Reported results | 2009-010147-14 | A diagnostic interventional, controlled, cross-sectional evaluation of joint status using MRI in subjects with severe hemophilia A treated with primary prophylaxis, secondary prophylaxis, or on-demand... | 2010-12-31 | due-trials |
| Reported results | 2009-010599-45 | Single-center, open-label, uncontrolled study to investigate the effects of the transdermal contraceptive patch containing 0.55 mg ethinylestradiol and 2.1 mg gestodene (material no. 80876395) on the ... | 2011-06-28 | due-trials |
| Reported results | 2009-010973-19 | A randomized, double-masked, sham-controlled phase 3 study of the efficacy, safety, and tolerability of repeated intravitreal administration of VEGF Trap-Eye in subjects with macular edema secondary t... | 2012-02-01 | due-trials |
| Reported results | 2009-011355-46 | A double blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of acetylsalicylic acid combined with pseudoephedrine, compared with acetylsalicylic acid alone, and pseud... | 2012-03-26 | due-trials |
| Reported results | 2009-012007-25 | A Double-Blind, Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer | 2017-08-30 | due-trials |
| Reported results | 2009-012149-43 | A two part randomized, cross-over, open-label trial to evaluate the pharmacokinetics, efficacy, and safety profile of plasma-protein free recombinant FVIII formulated with sucrose (BAY 81-8973) in pr... | 2013-03-14 | due-trials |
| Reported results | 2009-012150-20 | A phase II/III, randomized, cross-over, open-label trial to demonstrate superiority of prophylaxis over on-demand therapy in previously treated subjects with severe hemophilia A treated with plasma pr... | 2012-12-05 | due-trials |
| Reported results | 2009-012569-79 | An open-label, non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detection/exclusion of cerebral ß-amyloid when compar... | 2014-09-18 | due-trials |
| Reported results | 2009-012570-13 | An uncontrolled open label multicenter phase II safety study of BAY 73-4506 in patients with hepatocellular carcinoma (HCC) | 2013-03-13 | due-trials |
| Reported results | 2009-012787-14 | A randomized, double-blind, placebo-controlled phase III study of regorafenib plus BSC versus placebo plus BSC in patients with metastatic colorectal cancer (CRC) who have progressed after standard t... | 2014-01-22 | due-trials |
| Reported results | 2009-013081-17 | Open-label, multi-center, two-stage, age stratified, pharmacokinetic, safety, and efficacy study in children 2 month to < 2 years of age undergoing Magnevist Injection enhanced MRI | 2010-09-09 | due-trials |
| Reported results Terminated | 2009-014377-40 | A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY 58-2667 (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously t... | 2011-02-04 | due-trials |
| Reported results | 2009-014378-16 | A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of Low Dose BAY 58-2667 (25 μg/h, 10 μg/h) Given Intravenously to ... | 2011-03-01 | due-trials |
| Reported results | 2009-014911-11 | A multi-centre, randomized, double-blind, active control, parallel-group, 2-arm study to investigate the effect of ethinylestradiol / drospirenone / (0.02 mg/3 mg) oral contraception in a 24/4 regimen... | 2011-10-28 | due-trials |
| Trial is partly outside EEC, and reported results | 2009-015578-37 | A randomized, double-blind, multicenter trial to evaluate the safety and efficacy of sequential (intravenous, oral) moxifloxacin versus comparator in pediatric subjects with complicated intra-abdomina... | 2015-01-21 | bad-data |
| Listed as ongoing, but also has a completion date | 2009-015878-35 | Randomized, double blind, placebo controlled, parallel group, multi-center study to evaluate the hemodynamic effects of Riociguat (BAY 63-2521) as well as safety and kinetics in patients with pulmonar... | 2016-05-27 | bad-data |
| Reported results | 2009-017077-37 | A Multicenter, Multifactorial, Randomized, Double-Blind, Placebo-Controlled Dose- Finding Study of Nifedipine GITS and Candesartan in Combination Compared to Monotherapy in Adult Patients with Essenti... | 2012-05-29 | due-trials |
| Reported results | 2009-017082-39 | A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY 58-2667 (50 µg/h, 100 µg/h, 150 µg/h) Given Intravenously t... | 2012-01-12 | due-trials |
| Reported results Terminated | 2009-017139-16 | Effect of exercise alone or in combination with testosterone replacement on muscle strength and quality of life in older men with low testosterone concentrations: a randomized double-blind, placebo co... | 2011-07-06 | due-trials |
| Reported results | 2009-017169-53 | A multi-center, open label, single-arm study to investigate the safety and efficacy of daily oral administration of 2 mg dienogest tablets for the treatment of endometriosis in adolescents over a tre... | 2014-06-02 | due-trials |
| Reported results | 2009-017313-30 | Single-dose pilot study of oral rivaroxaban in pediatric subjects with venous thromboembolism | 2015-07-07 | due-trials |
| Reported results | 2009-017957-37 | A randomized, double-blind, placebo-controlled phase III study of regorafenib plus best supportive care versus placebo plus best supportive care for subjects with metastatic and/or unresectable gastro... | 2019-04-15 | due-trials |
| Reported results | 2010-018436-41 | Acute hemoDynamic effects of RIociguat (BAY 63-2521) in patients with puLmonary hypertension Associated with diasTolic heart failurE (DILATE 1): A randomized, double-blind, placebo-controlled, single... | 2012-10-19 | due-trials |
| Reported results | 2010-018501-10 | A Phase III Randomized, Double blind, Placebo-controlled Trial Comparing Capecitabine Plus Sorafenib Versus Capecitabine Plus Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative B... | 2018-10-20 | due-trials |
| Reported results | 2010-018863-40 | An interaction study to evaluate changes in blood pressure following 1, 1.5, 2, and 2.5 mg riociguat tid (dose titration) compared to placebo treatment on the background of stable sildenafil pretreatm... | 2013-05-14 | due-trials |
| Reported results | 2010-019588-12 | A multi-center, phase I/II study of BAY 86-9766 in combination with gemcitabine in patients with locally advanced inoperable or metastatic pancreatic cancer | 2013-08-01 | due-trials |
| Reported results | 2010-019902-17 | A multicenter, open-label, randomized, controlled, two-arm study to assess compliance with daily tablet intake of women on treatment with the oral contraceptive SH T00186D/BAY 86-5300 (0.02 mg ethinyl... | 2012-08-06 | due-trials |
| Reported results | 2010-020121-41 | An uncontrolled, open-label, phase II study in subjects with metastatic adenocarcinoma of the colon or rectum who are receiving first line chemotherapy with mFOLFOX6 (oxaliplatin/ folinic acid/5-fluor... | 2014-06-30 | due-trials |
| Reported results | 2010-020122-18 | A prospective, randomized, double-blind, double-dummy, placebo- and active controlled, multicenter study assessing the efficacy and safety of the combination BAY 60 4552 / vardenafil compared to varde... | 2011-05-31 | due-trials |
| Reported results | 2010-020181-21 | Multicenter, randomized, open-label, parallel-group study to evaluate user satisfaction with and tolerability of the low-dose levonorgestrel (LNG) intrauterine delivery system (IUS) with 12 µg LNG/day... | 2014-05-28 | due-trials |
| Reported results | 2010-020922-16 | International, prospective, double-blind, 3-arm comparative, randomized, placebo controlled phase IV study on the effect of counseling and either tranexamic acid or mefenamic acid or placebo, on the m... | 2011-12-22 | due-trials |
| Reported results | 2010-021195-28 | Single-center, randomized, placebo-controlled, double-blind, parallel group study to evaluate whether a single-dose of either 20 mg piroxicam, 40 mg piroxicam or 80 mg piroxicam shows an effect on ov... | 2012-05-29 | due-trials |
| Reported results | 2010-021255-81 | Multicenter, open-label, randomized study to evaluate inhibition of ovulation during treatment with three transdermal patch formulations containing 0.55 mg ethinylestradiol (EE) and 2.10 mg gestodene... | 2011-10-06 | due-trials |
| Reported results | 2010-021781-29 | A multicenter Phase III uncontrolled open-label trial to evaluate safety and efficacy of BAY 81-8973 in children with severe haemophilia A under prophylaxis therapy | 2020-10-27 | due-trials |
| Reported results | 2010-022364-12 | A randomized, double masked, active controlled, phase III study of the efficacy and safety of repeated doses of intravitreal VEGF Trap-Eye in subjects with diabetic macular edema | 2015-03-30 | due-trials |
| Reported results | 2010-023001-36 | Multicenter, open-label study to evaluate the safety and efficacy (by blinded reading) of contrast-enhanced magnetic resonance angiography (MRA) after a single intravenous injection of 0.1 mmol/kg gad... | 2014-05-28 | due-trials |
| Reported results | 2010-023002-13 | Multicenter, open-label study to evaluate the safety and efficacy (by blinded reading) of Gadobutrol-enhanced magnetic resonance angiography (MRA) after a single injection of 0.1 mmol/kg of Gadobutrol... | 2012-07-12 | due-trials |
| Reported results | 2010-023003-96 | Open-label, multicenter, pharmacokinetic, and safety study in children (term newborn infants to 23 months of age) undergoing a contrast-enhanced MRI with an intravenous injection of 0.1 mmol/kg BW gad... | 2013-12-17 | due-trials |
| Reported results | 2010-023586-22 | Prospective Case Crossover Study to Assess Whether PDE5 Inhibitor Exposure in Men Increases the Risk for the Development of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) | 2018-03-28 | due-trials |
| Reported results | 2010-023911-32 | Multicenter, open-label, randomized, controlled parallel-group study to assess discontinuation rates, bleeding patterns, user satisfaction and adverse event profile of LCS12 in comparison to etonogest... | 2015-04-30 | due-trials |
| Reported results | 2010-024332-42 | A randomized, double-blind, placebo-controlled phase II study to investigate the efficacy and safety of riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in patients with symptomatic pulmonary... | 2016-09-14 | due-trials |
| Reported results | 2011-000301-45 | A randomized, double-blind, multi-center study to assess safety and tolerability of different oral doses of BAY 94-8862 in subjects with stable chronic heart failure with left ventricular systolic dys... | 2012-06-12 | due-trials |
| Reported results | 2011-000323-33 | A Phase 2/3, multicenter, open-label clinical study to assess the safety and efficacy of BAY86-6150 in subjects with hemophilia A or B with inhibitors, composed of 2 Parts (A & B). Part A: Sequential ... | 2013-04-30 | due-trials |
| Reported results | 2011-001094-58 | Prospective, multi-center, randomized, heparin-controlled dose-finding trial to evaluate the efficacy and safety of rivaroxaban, a direct factor Xa inhibitor, on the background of standard dual antipl... | 2013-03-04 | due-trials |
| Reported results | 2011-001893-24 | Relative bioavailability and food effect study of two oral liquid formulations in comparison to a 1mg tablet of riociguat to characterize its pharmacokinetic properties in healthy male and female adul... | 2012-05-12 | due-trials |
| Reported results | 2011-002065-37 | Multi-center, single-arm study to assess the safety, efficacy, discontinuation rate and pharmacokinetics of the low-dose levonorgestrel intrauterine contraceptive system (LCS12) in post-menarcheal fem... | 2015-05-28 | due-trials |
| Reported results | 2011-002234-39 | A prospective, randomized, open-label, parallel-group, active-controlled, multicenter study exploring the efficacy and safety of once-daily oral rivaroxaban (BAY 59-7939) compared with that of dose-ad... | 2014-01-24 | due-trials |
| Exempt, with results | 2011-004155-39 | Phase Ib / II study of BAY 1000394 in combination with cisplatin / etoposide or carboplatin / etoposide as first-line therapy in subjects with extensive disease small cell lung cancer | 2016-03-08 | not-yet-due |
| Reported results | 2011-004208-39 | Randomized, double-blind, placebo-controlled, multicEnter Study comParing CIprofloxacin DPI 32.5 mg BID intermittently administered for 28 days on / 28 days off or 14 days on / 14 days off versus plac... | 2016-03-09 | due-trials |
| Reported results | 2011-004539-30 | 30 day, single-arm study of the safety, efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in children with various manifestations of venous thrombosis | 2016-09-01 | due-trials |
| Trial is partly outside EEC, and reported results | 2011-005210-11 | A Phase II/III, multicenter, partially randomized, open label trial investigating safety and efficacy of on-demand and prophylactic treatment with BAY 94-9027 in Severe Hemophilia A | 2019-11-21 | bad-data |
| Reported results | 2011-005836-25 | An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy Studio di fase IIIb in aperto sull'uso di regorafenib i... | 2019-04-30 | due-trials |
| Reported results | 2012-000075-16 | Radium-223 Chloride (Alpharadin) in Castration-Resistant (Hormone- Refractory) Prostate Cancer Patients with Bone Metastasis Cloruro di radio-223 (Alpharadin) nei pazienti affetti da tumore alla p... | 2016-02-28 | due-trials |
| Trial is outside EEC, and reported results | 2012-000737-40 | Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients | bad-data | |
| Trial is outside EEC, and reported results | 2012-000952-32 | Open-label, multi-center study to evaluate the safety, efficacy, and plasma gadolinium concentrations after an intravenous injection of 0.1 mL/kg body weight Eovist/Primovist for enhanced magnetic res... | bad-data | |
| Reported results | 2012-001062-15 | An open-label, international, multicenter, interventional study exploring the efficacy of once-daily oral rivaroxaban (BAY 59-7939) for the treatment of left atrial/left atrial appendage thrombus in s... | 2014-12-25 | due-trials |
| Reported results | 2012-002104-40 | An open-label phase IIIb study of riociguat in patients with in-operable CTEPH, or recurrent or persisting PH after surgical treatment who are not satisfactorily treated and cannot participate in any... | 2015-12-01 | due-trials |
| Reported results | 2012-002563-10 | Multicenter open-label study to evaluate efficacy of gadobutrol-enhanced cardiac magnetic resonance imaging (CMRI) for detection of significant coronary artery disease (CAD) in subjects with known or ... | 2017-08-31 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2012-002602-52 | Open-label, uncontrolled Phase II trial of intravenous PI3K inhibitor BAY 80-6946 in patients with relapsed, indolent or aggressive Non-Hodgkin's lymphomas Ensayo fase II, abierto, no controlado de... | 2023-05-18 | bad-data |
| Reported results | 2012-002627-15 | A randomized, double-blind, double-dummy, multi-center study to assess safety and efficacy of BAY 94-8862 in subjects with emergency presentation at the hospital because of worsening chronic heart fai... | 2014-12-09 | due-trials |
| Reported results | 2012-003649-14 | A randomized, double blind, placebo-controlled, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib | 2019-07-31 | due-trials |
| Reported results | 2012-003650-88 | A randomized, open-label, active-controlled, Phase II study of intravenous anetumab ravtansine (BAY 94-9343) or vinorelbine in patients with advanced or metastatic malignant pleural mesothelioma hyper... | 2019-09-06 | due-trials |
| Reported results Terminated | 2012-003763-22 | A combined Phase IIa / IIb study of the efficacy, safety, and tolerability of repeated topical doses of regorafenib eye drops, in treatment-naïve subjects with neovascular age related macular degenera... | 2015-07-16 | due-trials |
| Reported results | 2012-004179-38 | A randomized, double-blind, placebo-controlled, multi-center study to assess the safety and efficacy of different oral doses of BAY 94-8862 in subjects with type 2 diabetes mellitus and the clinical d... | 2014-08-07 | due-trials |
| Reported results | 2012-004180-43 | A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People usin... | 2021-06-15 | due-trials |
| Reported results | 2012-004369-42 | A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients with Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases | 2016-09-28 | due-trials |
| Trial is partly outside EEC, and reported results | 2012-004434-42 | A multi-center, phase III, non-controlled, open-label trial to evaluate the pharmacokinetics, safety, and efficacy of BAY 94-9027 for prophylaxis and treatment of bleeding in previously treated childr... | 2020-02-19 | bad-data |
| Reported results | 2012-004491-18 | A Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety and Efficacy of 28 Day Oral Administration of BAY 85-8501 in Patients with non-Cystic Fibrosis Bron... | 2014-06-13 | due-trials |
| Reported results | 2012-004493-26 | A Multicenter, Randomized, Double-Blind, Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination Taken Orally for 8 Weeks in Adult Subje... | 2016-09-28 | due-trials |
| Reported results | 2012-004515-32 | Multicenter, Open-Label, Long-Term Safety and Efficacy Study of the Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Adult Subjects with Moderate t... | 2014-05-01 | due-trials |
| Completed, but no date, and reported results | 2012-004857-10 | A Multicenter, Randomized, Double-Blind, Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination Taken Orally for 8 Weeks in Adult Subje... | bad-data | |
| Reported results | 2012-005262-35 | BENEFIT 11 a long-term, follow-up study (16401) of the BENEFIT (304747), BENEFIT Follow-up (305207) Studies and BENEFIT Extension (311129) Study to further evaluate the progress of patients with first... | 2014-06-18 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2013-000120-33 | An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of 2 mg aflibercept administered by intravitreal injections using two different t... | 2020-06-04 | bad-data |
| Reported results | 2013-000241-39 | A prospective, single-arm, multicenter, uncontrolled, open-label Phase II trial of refametinib (BAY 86-9766) in combination with sorafenib as first line treatment in patients with RAS mutant Hepatocel... | 2017-03-13 | due-trials |
| Reported results | 2013-000311-25 | A prospective, single-arm, multicenter, uncontrolled, open-label Phase II trial of refametinib (BAY 86-9766) in patients with RAS mutant Hepatocellular Carcinoma (HCC) | 2014-10-08 | due-trials |
| Reported results | 2013-000619-26 | Reduced-dosed rivaroxaban and standard-dosed rivaroxaban versus ASA in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis and/or... | 2016-11-04 | due-trials |
| Reported results | 2013-000768-27 | Multicenter, randomized, double-blind, double-dummy, active-comparator, event-driven, superiority phase III study of secondary prevention of stroke and prevention of systemic embolism in patients with... | 2019-02-15 | due-trials |
| Reported results | 2013-001048-73 | A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Patient... | 2017-11-10 | due-trials |
| Reported results | 2013-001190-24 | A controlled, parallel group, open-label, multicenter extension study to investigate efficacy and safety of oral BAY 85-3934 and darbepoetin alfa comparator in the long term treatment of anemia in pre... | 2016-12-16 | due-trials |
| Reported results | 2013-001192-21 | A randomized, parallel group, open-label, multicenter study to investigate the efficacy and safety of oral BAY 85-3934 and active comparator (darbepoetin alfa) in the maintenance treatment of anemia i... | 2015-11-23 | due-trials |
| Reported results | 2013-001193-14 | A randomized, placebo-controlled, double-blind, parallel group, multicenter study to investigate the efficacy and safety of 5 fixed doses of BAY 85- 3934 administered orally in the correction of anemi... | 2015-10-23 | due-trials |
| Reported results | 2013-001287-34 | A single blind, placebo controlled pilot study to explore the safety and tolerability of a single oral dose of 30 mg BAY 1067197 in patients with chronic heart failure on the background of preexisting... | 2015-03-17 | due-trials |
| Reported results | 2013-001759-10 | An open-label, international, multicenter, single-arm, uncontrolled, phase IIIb study of riociguat in patients with pulmonary arterial hypertension (PAH) who demonstrate an insufficient response to tr... | 2016-12-29 | due-trials |
| Reported results | 2013-001899-38 | Single dose, double-blind, placebo-controlled, single center, randomized cross-over study to investigate safety, tolerability, pharmacodynamics and pharmacokinetic properties of BAY 63-2521 after oral... | 2014-11-07 | due-trials |
| Reported results | 2013-002287-11 | A randomized parallel-group, placebo-controlled, double-blind, multi-center dose finding phase II trial exploring the pharmacodynamic effects, safety and tolerability, and pharmacokinetics of four dos... | 2015-06-22 | due-trials |
| Reported results | 2013-002288-25 | A randomized parallel-group, placebo-controlled, double-blind, multi-center dose finding phase II trial exploring the pharmacodynamic effects, safety and tolerability, and pharmacokinetics of four dos... | 2015-09-16 | due-trials |
| Reported results | 2013-002522-23 | A double blinded, placebo controlled, study to investigate the safety, tolerability, pharmacokinetics and acute cardiovascular responses of a 7 day oral treatment with the partial adenosine A1 recepto... | 2016-04-02 | due-trials |
| Exempt, with results | 2013-002783-12 | A multi-center, open-label, randomized cross-over study to compare the acute tolerability and pharmacokinetics of BAY Q 6256 (iloprost; Ventavis) inhalation using the I-Neb nebulizer and the FOX nebul... | 2017-09-29 | not-yet-due |
| Reported results | 2013-003046-17 | A re-treatment safety study of radium-223 dichloride in subjects with castration-resistant prostate cancer with bone metastases who received an initial course of six doses of radium-223 dichloride 50 ... | 2017-04-12 | due-trials |
| Reported results | 2013-003118-42 | A three arm randomized, open-label Phase II study of radium-223 dichloride 50 kBq/kg (55 kBq/kg after implementation of NIST update) versus 80 kBq/kg (88 kBq/kg after implementation of NIST update), a... | 2018-08-09 | due-trials |
| Completed, reported early | 2013-003438-33 | A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly s... | 2024-02-08 | not-yet-due |
| Listed as ongoing, but also has a completion date and reported results | 2013-003579-36 | A multi-center, open-label, non-randomized, phase I dose escalation study of regorafenib (BAY 73-4506) in pediatric subjects with solid malignant tumors that are recurrent or refractory to standard th... | 2016-05-27 | bad-data |
| Reported results | 2013-003820-36 | A MULTINATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III EFFICACY AND SAFETY STUDY OF DAROLUTAMIDE (DCM-201) IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | 2021-06-16 | due-trials |
| Ongoing, reported early | 2013-003893-29 | A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin's l... | not-yet-due | |
| Reported results | 2013-003945-40 | A randomized, parallel-group, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of different doses of BAY 1002670 in subjects with uterine fibroids over 3 months | 2016-05-05 | due-trials |
| Reported results | 2013-003980-74 | Multi-center, randomized, comparator-controlled, single-blind, parallel-group study to investigate the pharmacodynamics, pharmacokinetics and safety of an intrauterine system releasing BAY 1007626, as... | 2016-05-26 | due-trials |
| Reported results | 2013-004198-28 | A randomized, double blind, placebo-controlled, multicenter phase II study to evaluate efficacy and safety of roniciclib in subjects with extensive-stage disease small cell lung cancer (SCLC) who are ... | 2016-05-25 | due-trials |
| Reported results | 2013-004464-54 | A randomized, double-masked, sham-controlled phase 3b/4 study of the efficacy, safety, and tolerability of intravitreal aflibercept monotherapy compared to aflibercept with adjunctive photodynamic the... | 2017-07-07 | due-trials |
| Reported results | 2013-004595-35 | Multi-center phase 2 study to assess the safety, tolerability and early signs of efficacy of tid orally administered BAY63-2521 in adult deltaF508 homozygous Cystic Fibrosis patients | 2017-08-31 | due-trials |
| Reported results | 2013-004659-19 | Randomized, double-blind, placebo-controlled, multicenter study comparing Ciprofloxacin DPI 32.5 mg BID intermittently administered for 28 days on / 28 days off or 14 days on / 14 days off versus plac... | 2016-10-19 | due-trials |
| Reported results | 2013-004768-72 | A randomized, double-blind, parallel-group, multicenter Phase 2b study to assess the efficacy and safety of two different doses of vilaprisan (BAY 1002670) versus placebo in women with symptomatic end... | 2020-11-26 | due-trials |
| Reported results | 2013-005090-53 | A randomized, double-blind, double-dummy, parallel- group, multi-center phase IIb study to assess the efficacy and safety of different dose combinations of an aromatase inhibitor and a progestin in an... | 2016-10-24 | due-trials |
| Reported results | 2014-000565-47 | Multicenter, open-label, active-controlled, randomized study to evaluate the efficacy and safety of an age-and body weight-adjusted rivaroxaban regimen compared to standard of care in children with ac... | 2019-01-30 | due-trials |
| Reported results | 2014-000566-22 | 30-day, open-label, active-controlled, randomized study of the safety, efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in young children with various manifestations... | 2017-05-04 | due-trials |
| Reported results | 2014-000925-19 | A randomized, double-blind Phase III study of copanlisib versus placebo in patients with rituximab-refractory indolent non-Hodgkin's lymphoma (iNHL) - CHRONOS-2 Studio randomizzato, in doppio cieco... | 2022-10-26 | due-trials |
| Reported results | 2014-001353-16 | A Randomised, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc) | 2019-03-28 | due-trials |
| Trial is outside EEC, and reported results | 2014-001362-10 | Routine prophylaxis treatment versus On-demand treatment for Children with severe Hemophilia A: comparison of all bleeding events in Chinese Hemophilia patients | bad-data | |
| Reported results | 2014-002113-39 | A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride versus placebo when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects wit... | 2019-08-13 | due-trials |
| Reported results | 2014-002114-23 | A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with exemestane and everolimus versus placebo in combination with exemestane and everolimus when a... | 2022-10-28 | due-trials |
| Exempt, with results | 2014-002385-74 | 7-day study of the safety, efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in children from birth to less than 6 months with arterial or venous thrombosis. | 2017-12-18 | not-yet-due |
| Listed as ongoing, but also has a completion date | 2014-002407-25 | A Phase 4 long-term follow-up study to define the safety profile of radium-223 dichloride | 2024-01-31 | bad-data |
| Reported results | 2014-003132-39 | Managing neovascular age-related macular degeneration (nAMD) over 2 years with a Treat and Extend (T&E) regimen of 2 mg intravitreal (IVT) aflibercept - a randomized, open-label, active-controlled, pa... | 2019-04-26 | due-trials |
| Reported results | 2014-003193-17 | A multi center, single arm, interventional Phase 4 study to evaluate a Treat and Extend regimen of intravitreal aflibercept for treatment of macular edema secondary to central retinal vein occlusion | 2019-07-31 | due-trials |
| Trial is partly outside EEC, and reported results | 2014-003952-29 | Open-label, individual dose titration study to evaluate safety, tolerability and pharmacokinetics of riociguat in children from 6 to less than 18 years of age with pulmonary arterial hypertension (PAH... | 2016-05-27 | bad-data |
| Reported results | 2014-004221-41 | A randomized, parallel-group, double-blind placebo-controlled and open label active-controlled, multi-center study to assess the efficacy and safety of vilaprisan in patients with uterine fibroids | 2016-10-28 | due-trials |
| Trial is outside EEC, and reported results | 2014-004612-10 | A multicenter, double-blind, randomized, placebo controlled study to evaluate the efficacy and safety of an oral contraceptive preparation YAZ (drospirenone 3 mg / ethinylestradiol 20 µg) for 6 treatm... | bad-data | |
| Trial is outside EEC, and reported results | 2014-004613-93 | Open label study to evaluate the effect, safety and tolerability of 250µg (8 MIU) interferon beta 1b (Betaferon) given subcutaneously every other day (for 24 weeks) in patients of Chinese origin with ... | bad-data | |
| Trial is outside EEC, and reported results | 2014-004622-18 | A prospective, open-label, non-randomized, naturalistic, long-term safety surveillance, observational study of either ciprofloxacin (either as oral suspension, oral tablets or sequential IV followed b... | bad-data | |
| Reported results | 2014-004848-36 | An open-label, single-arm Phase II study in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) to evaluate efficacy and safety of treatment with single agent copanlisib and the... | 2018-01-19 | due-trials |
| Reported results | 2014-004938-25 | An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of three different treatment regimens of 2 mg aflibercept administered by intravi... | 2019-09-24 | due-trials |
| Reported results | 2014-005119-17 | Open-label Phase-4 study to examine the change of vision-related quality of life in subjects with diabetic macular edema (DME) during treatment with intravitreal injections of 2 mg aflibercept accordi... | 2017-08-09 | due-trials |
| Trial is outside EEC, and reported results | 2014-005253-39 | A Prospective Study to Evaluate the Effect of rFVIII-FS in Different Prophylactic Regimens on Bleeding Events Frequency and Development of Arthropathy in Previously Treated and Minimally Treated Hemop... | bad-data | |
| Trial is outside EEC, and reported results | 2014-005268-13 | An Open Label, Actual Use Study in Consumers Taking an Extended-Release Over the Counter NSAID in a Naturalistic Setting | bad-data | |
| Trial is outside EEC, and reported results | 2014-005269-66 | A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Trial Assessing the Analgesic Efficacy of a Single, Oral Dose of an Extended Release Naproxen Sodium Tablet in Postsurgical Dental... | bad-data | |
| Trial is outside EEC, and reported results | 2014-005270-11 | Comparative Onset of Action of a Fast Release Aspirin Tablet in a Dental Impaction Pain Model | bad-data | |
| Trial is outside EEC, and reported results | 2014-005271-81 | A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Trial Assessing the Analgesic Efficacy of a Single, Oral Dose of a Fast Release Aspirin 1000 mg in Postsurgical Dental Pain | bad-data | |
| Trial is outside EEC, and reported results | 2014-005272-28 | A Randomized, Double-Blind, Placebo Controlled Trial to Assess the Analgesic Efficacy and Safety of Extended Release Naproxen Sodium Tablets in Postsurgical Dental Pain | bad-data | |
| Trial is outside EEC, and reported results | 2014-005278-12 | A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Trial Assessing the Analgesic Efficacy of a Single, Oral Dose of a Fast Release Aspirin 650 mg in Postsurgical Dental Pain | bad-data | |
| Reported results | 2014-005297-12 | A single blind, multicenter pilot study to investigate the safety and tolerability of a 14 day oral treatment with different doses of the chymase inhibitor BAY 1142524 in comparison to placebo in clin... | 2016-03-04 | due-trials |
| Trial is outside EEC, and reported results | 2014-005305-20 | A Pilot Self Selection Trial of an Extended-Release Over-the-Counter Analgesic | bad-data | |
| Trial is outside EEC, and reported results | 2014-005316-41 | An Actual Use Trial In A Simulated OTC Environment of an Extended-Release Over-the-Counter NSAID | bad-data | |
| Reported results | 2014-005569-58 | An international, multicenter, randomized, double-blind, placebo-controlled phase 3 trial investigating the efficacy and safety of Rivaroxaban to reduce the risk of major thrombotic vascular events i... | 2020-01-09 | due-trials |
| Reported results | 2015-000950-39 | A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbid... | 2021-02-02 | due-trials |
| Exempt, with results | 2015-000962-76 | Single-dose study testing a rivaroxaban dry powder formulation for oral suspension in children from 6 months to 12 years with previous thrombosis | 2018-05-22 | not-yet-due |
| Reported results | 2015-000990-11 | A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the ... | 2020-04-14 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2015-001088-38 | A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in pati... | 2023-11-10 | bad-data |
| Reported results | 2015-001975-30 | Global multicenter, open-label, randomized, event-driven, active-controlled study comparing a rivAroxaban-based antithrombotic strategy to an antipLatelet-based strategy after transcatheter aortIc vaL... | 2018-11-27 | due-trials |
| Reported results Terminated | 2015-002168-17 | A multicenter, randomized, double-blind, double-dummy, parallel-group, active-controlled study to evaluate the efficacy and safety of finerenone compared to eplerenone on morbidity and mortality in pa... | 2016-03-11 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2015-002590-38 | A randomized, double-blind, placebo-controlled Phase III study of ODM-201 versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitiv... | 2023-04-11 | bad-data |
| Ongoing | 2015-003582-28 | A Phase 2 Basket Study of the Oral TRK Inhibitor Larotrectinib in Subjects with NTRK Fusion-Positive Tumors P/0401/2019 Eine Phase-II-Basket-Studie des oralen TRK-Inhibitors Larotrectinib bei Prob... | not-yet-due | |
| Reported results | 2015-003799-63 | A randomized, single blind, threefold crossover, single center study to assess the safety and the effects of 1 mg and 5 mg BAY 1193397 in comparison to placebo on skin capillary blood flow and transcu... | 2019-10-28 | due-trials |
| Completed, but no date | 2016-000501-36 | An open-label, multi-national, multi-center, single-arm, uncontrolled, long-term extension study of orally administered riociguat in patients with symptomatic pulmonary arterial hypertension (PAH) who... | bad-data | |
| Reported results | 2016-001067-36 | A prospective, randomized, international, multicenter, double-arm, controlled, open-label study of Riociguat in patients with pulmonary arterial hypertension (PAH) who are on a stable dose of phospho... | 2020-03-30 | due-trials |
| Reported results | 2016-002167-33 | A randomized, double-blind multicenter study to assess the safety and efficacy of a six month oral treatment with the chymase inhibitor BAY 1142524 at a dose of 25 mg BID in comparison to placebo on t... | 2018-09-04 | due-trials |
| Exempt, with results | 2016-002438-58 | A phase 1b/2 trial to evaluate the safety and efficacy of radium-223 dichloride (BAY 88-8223) in combination with bortezomib and dexamethasone in early relapsed multiple myeloma Ensayo de fase Ib/I... | 2019-03-20 | not-yet-due |
| Reported results | 2016-002681-31 | A randomized, active-comparator-controlled, multicenter study to assess the safety and efficacy of different doses of BAY 1213790 for the prevention of venous thromboembolism in patients undergoing el... | 2019-01-02 | due-trials |
| Reported results | 2016-002813-24 | Relative bioavailability study to investigate the pharmacokinetics, safety and tolerability of a single oral dose of finerenone 20 mg as suspension (pediatric formulation), intact tablet and crushed t... | 2017-03-01 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-002855-48 | A randomized, parallel-group, double-blind, multicenter study to assess the efficacy and safety of vilaprisan in subjects with uterine fibroids | 2021-10-28 | bad-data |
| Reported results | 2016-002895-29 | Relative bioavailability study to investigate the pharmacokinetics, safety and tolerability of single oral doses of finerenone 1.25 mg and 5 x 0.25 mg oro-dispersible tablet (pediatric formulation) in... | 2017-03-17 | due-trials |
| Ongoing | 2016-003498-16 | A Phase 1/2 Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors | not-yet-due | |
| Reported results | 2016-003561-26 | A randomized, parallel-group, double-blind and placebo-controlled, multicenter study to assess the efficacy and safety of vilaprisan in subjects with uterine fibroids Randomizované, dvojitě zaslepe... | 2021-06-30 | due-trials |
| Reported results | 2016-003839-38 | A multicenter, randomized, placebo-controlled, parallel group, double blind, dose-finding Phase II trial to study the efficacy, safety, pharmacokinetic and pharmacodynamic effects of the oral partial ... | 2018-05-16 | due-trials |
| Reported results | 2016-004062-26 | A multicenter, randomized, placebo-controlled, parallel group, double blind, dose-finding Phase II trial to study the efficacy, safety, pharmacokinetic and pharmacodynamic effects of the oral partial ... | 2018-07-20 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-004340-11 | A randomized, open label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metas... | 2020-10-27 | bad-data |
| Exempt, with results | 2016-004484-39 | An open-label, first-in-human, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose and / or recommended Phase II dose of the ATR ... | not-yet-due | |
| Reported results | 2016-004822-41 | An open-label, parallel-group, randomized, multicenter study to assess the safety and efficacy of vilaprisan in subjects with uterine fibroids versus standard of care | 2021-10-12 | due-trials |
| Reported results Terminated | 2017-000244-18 | A randomized, placebo-controlled, double-blind, parallel-group, multi-center, exploratory dose-response study to assess the efficacy and safety of different oral doses of BAY 1128688 in women with sym... | 2018-10-22 | due-trials |
| Trial is outside EEC, and reported results | 2017-000383-15 | A non-randomized, open-label, multi-center, Phase I/II study of PI3K inhibitor copanlisib in pediatric patients with relapsed/refractory solid tumors or lymphoma | bad-data | |
| Reported results | 2017-000609-18 | Single-dose, open-label, randomized, 2-way crossover bioequivalence study of 20 mg granules for oral suspension rivaroxaban versus 20 mg tablets rivaroxaban under fed condition in healthy subjects | 2017-10-27 | due-trials |
| Reported results | 2017-000648-16 | Single-dose, open-label, randomized, 2-way crossover bioequivalence study of 10 mg granules for oral suspension rivaroxaban versus 10 mg tablets rivaroxaban under fasted condition in healthy subjects | 2017-10-27 | due-trials |
| Reported results | 2017-000656-26 | A randomized, double-blind, multicenter study to assess the efficacy and safety of a 6 month oral treatment with the chymase inhibitor BAY 1142524 at a dose of 25 mg BID in comparison to placebo on to... | 2019-10-10 | due-trials |
| Exempt | 2017-000806-39 | A phase 1/2 open-label safety and dose-finding study of BAY 2599023 (DTX201), an adeno-associated virus (AAV) hu37-mediated gene transfer of B-domain deleted human factor VIII, in adults with severe h... | not-yet-due | |
| Reported results | 2017-001176-31 | BENEFIT 15 long-term follow-up study of the BENEFIT and BENEFIT follow-up studies | 2018-05-24 | due-trials |
| Exempt | 2017-001483-38 | An international, multicenter, Phase 1b/2 study of rogaratinib (BAY 1163877) in combination with atezolizumab as first-line treatment in cisplatin-ineligible patients with FGFR-positive locally advanc... | 2024-07-10 | not-yet-due |
| Reported results Terminated | 2017-001851-29 | Randomized, multi-center, double-blind, placebo-controlled, group-comparison study to investigate safety, tolerability and pharmacodynamics of BAY2253651 after administration of a single nasal dose in... | 2019-05-23 | due-trials |
| Reported results | 2017-002997-38 | A randomized, parallel-group, double-blind and open-label, placebo-controlled, multicenter study to assess the efficacy and safety of vilaprisan in subjects with uterine fibroids Dvojitě zaslepené ... | 2022-04-06 | due-trials |
| Reported results | 2017-003324-67 | Multiple escalating dose study of BAY 1093884 in adults with hemophilia A or B with or without inhibitors | 2019-10-15 | due-trials |
| Exempt, with results | 2017-004246-20 | A Phase 1 Study of the TRK Inhibitor Selitrectinib (BAY 2731954) in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers Formerly: A Phase 1/2 Study of the TRK Inhibitor LOXO-195 ... | 2023-01-30 | not-yet-due |
| Trial is outside EEC, and reported results | 2017-005031-17 | A Double-Blind, Randomized, Crossover Study to Assess Menstrual Cramp Pain Associated with Primary Dysmenorrhea | bad-data | |
| Trial is outside EEC, and reported results | 2017-005049-67 | A Randomized, Double-Blind, Placebo-Controlled Trial to Compare the Duration of Analgesic Efficacy and Safety of Naproxen Sodium Tablets and Ibuprofen Tablets in Postsurgical Dental Pain | bad-data | |
| Reported results | 2018-000128-33 | Multi-center, randomized, comparator-controlled, single-blind, parallel-group study to investigate the pharmacodynamics, pharmacokinetics and safety of an intrauterine system (BAY 987443) with three d... | 2019-08-01 | due-trials |
| Reported results | 2018-000298-65 | A randomized parallel-group, placebo-controlled, double-blind, multi-center trial to eValuate the effIcacy and safeTy of the orAL sGC stImulator vericiguaT to improve phYsical functioning in activitie... | 2019-11-04 | due-trials |
| Reported results | 2018-000690-78 | LowEr Administered Dose with highEr Relaxivity: Gadovist vs Dotarem | 2020-05-26 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2018-002611-99 | Open-label, randomized, two–arm, controlled study to assess the efficacy, safety, and tolerability of intravitreal (IVT) aflibercept compared to laser photocoagulation in patients with retinopathy of ... | 2021-02-12 | bad-data |
| Ongoing | 2018-003180-54 | An extension study to evaluate the long-term outcomes of patients who received treatment for retinopathy of prematurity in study 20090 Допълнително изпитване за дългосрочна оценка на изхода от лече... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2018-003650-24 | A single arm, open-label, multicenter Phase 2 study of regorafenib in participants who have been treated in a previous Bayer-sponsored regorafenib study (monotherapy or combination treatment) that has... | 2023-01-30 | bad-data |
| Reported results | 2018-003655-37 | Post-marketing investigation (PMI) to assess safety and efficacy of Jivi® (BAY 94-9027) treatment in patients with hemophilia A | 2022-08-26 | due-trials |
| Exempt, with results | 2018-003704-39 | An open-label, multicenter, Phase 1/2 study of radium-223 dichloride in combination with pembrolizumab in participants with stage IV non-small cell lung cancer | 2023-01-30 | not-yet-due |
| Reported results | 2018-004059-18 | A Multicenter, Randomized, Parallel Group, Double Blind, Active and Placebo Controlled Study of BAY 1753011, a Dual V1a/V2 Vasopressin Receptor Antagonist, in Patients with Congestive Heart Failure: A... | 2021-05-21 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2019-000061-20 | An open-label, multicenter rollover study to provide continued treatment with anetumab ravtansine for participants with solid tumors who were enrolled in previous Bayer-sponsored studies. | 2022-05-18 | bad-data |
| Other | 2019-000476-42 | A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of novel anti-hormonal therapy (NAH) in patients with bone dominan... | not-yet-due | |
| Reported results | 2019-001078-27 | Safety and efficacy of inhaled pegylated adrenomedullin (PEG-ADM) in patients suffering from Acute Respiratory Distress Syndrome (ARDS): a double-blind, randomized, placebo-controlled, multicenter Pha... | 2023-03-01 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2019-001560-30 | Multicenter, single-blind, adaptive dose finding study of single intravenous injections of BAY 1747846 with corresponding blinded read in adult participants with known or highly suspected CNS lesions ... | 2022-12-14 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2019-002365-35 | Multicenter, randomized, active comparator-controlled, double-blind, double-dummy, parallel group, dose-finding Phase 2 study to compare the safety of the oral FXIa inhibitor BAY 2433334 to apixaban i... | 2021-10-08 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2019-002575-34 | A randomised, placebo-controlled, double-blind, parallel-group, multi-centre, proof-of-concept study to assess the efficacy and safety of BAY 1817080 in patients with overactive bladder (OAB) over a 1... | 2022-01-21 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2019-003244-79 | Multicenter, randomized, placebo controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate the efficacy and safety of BAY 2433334 in patients following an acute myocardial infar... | 2022-02-21 | bad-data |
| Reported results | 2019-003297-53 | A randomized, double-blind, placebo-controlled, multi-center study to assess the safety and efficacy of individually titrated oral doses of runcaciguat in subjects with clinical diagnosis of chronic k... | 2022-04-05 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2019-003431-33 | Multicenter, randomized, placebo-controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate efficacy and safety of BAY 2433334 in patients following an acute non-cardioembolic is... | 2022-02-18 | bad-data |
| Trial is outside EEC, and reported results | 2019-003513-33 | A Randomized, Double-Blind, Single-Dose, Parallel, Placebo-Controlled Trial to Determine the Dose of Caffeine in a Fixed Dose Combination Tablet of Naproxen Sodium and Caffeine to Effectively Alleviat... | bad-data | |
| Listed as ongoing, but also has a completion date | 2019-003618-15 | An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer-sponsored studies | 2021-06-14 | bad-data |
| Listed as ongoing, but also has a completion date | 2019-003851-12 | Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration | 2024-08-07 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2019-003927-39 | Factor XI LICA to Reduce Thrombotic Events in End-Stage Renal Disease Patients on Hemodialysis: A Phase 2, Randomized, Double-Blind, Placebo- Controlled Study of the Safety, Pharmacokinetics, and Phar... | 2022-05-12 | bad-data |
| Reported results | 2019-003957-27 | A randomized, double-blind, parallel group, placebo-controlled, multi-center study to assess the safety and tolerability of monthly subcutaneous administrations of a low and high dose cohort of osocim... | 2022-06-30 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2019-004169-42 | Randomized, double-blind, parallel group, Phase 2b dose-finding, efficacy and safety study of 12-week twice daily oral administration of BAY 1817080 compared to placebo in the treatment of refractory ... | 2021-07-23 | bad-data |
| Reported results Terminated | 2019-004480-48 | A prospective, lead-in study to collect bleeding episodes, Factor VIII (FVIII) infusions, and patient-reported outcomes in patients with hemophilia A | 2022-08-04 | due-trials |
| Listed as ongoing, but also has a completion date | 2020-000306-29 | A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA ... | 2024-06-14 | bad-data |
| Reported results | 2020-000520-19 | Proof-of-concept, multi-center, randomized, double-blind, placebo-controlled, two-way crossover study to investigate the effect strength of BAY 2586116 on the apnea-hypopnea-index after repetitive nas... | 2021-11-11 | due-trials |
| Reported results | 2020-002066-14 | A randomized, placebo-controlled, double-blind, parallel-group, multicenter combined Phase 2a/2b study to assess the efficacy and safety of BAY 1817080 in patients with diabetic neuropathic pain | 2021-12-17 | due-trials |
| Reported results Terminated | 2020-002192-35 | A randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of BAY 2327949 in patients with chronic kidney disease (eGFR range from 25 to 60 mL/min/1.73 m²) du... | 2021-05-05 | due-trials |
| Completed, report not yet due | 2020-002333-15 | A Phase 2 randomized, placebo-controlled, double-masked proof-of concept study to investigate the efficacy and safety of runcaciguat (BAY 1101042) in patients with moderately severe to severe non-prol... | 2024-04-22 | not-yet-due |
| Other | 2020-003093-48 | A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus placebo plus ADT in men with metastatic hormone-sensitive prostate... | not-yet-due | |
| Reported results | 2020-003131-16 | A randomized, double-blind, open for active comparator, parallel-group, multicenter Phase 2b study to assess the efficacy and safety of three different doses of P2X3 antagonist (BAY 1817080) versus pl... | 2022-05-03 | due-trials |
| Listed as ongoing, but also has a completion date | 2020-003359-13 | A Multi-indication, Single-treatment Arm, Open-label Phase 2 Study of Regorafenib and Nivolumab in Combination in Patients with Recurrent or Metastatic Solid Tumors | 2024-03-29 | bad-data |
| Listed as ongoing, but also has a completion date | 2020-003555-16 | An Open-Label Study of Regorafenib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Hepatocellular Carcinoma (HCC) after PD-1/PD-L1 Immune Checkpoint Inhibitors | 2024-04-23 | bad-data |
| Reported results | 2020-003865-20 | A clinical trial collecting Data from routine ophthalmological examinations of patients who were randomized to either finerenone or placebo in the two Bayer-sponsored Phase 3 clinical trials FIDELIO-D... | 2021-07-02 | due-trials |
| Reported results | 2020-004343-92 | Randomized, Controlled, Double-blind, Placebo-controlled, Multi-center Hypothesis-finding Trial to Compare the Efficacy and Safety of a 10% Naproxen Gel vs. a 2.32% Diclofenac Diethylamine Gel and Pla... | 2021-12-20 | due-trials |
| Reported results | 2020-004855-34 | A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 26 weeks in postmenopausal women | 2023-10-04 | due-trials |
| Listed as ongoing, but also has a completion date | 2020-004908-33 | A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 26 weeks in postmenopausal women | 2023-11-27 | bad-data |
| Completed, report not yet due | 2021-000059-38 | A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 52 weeks in postmenopausal women. | 2024-02-12 | not-yet-due |
| Other | 2021-000421-27 | A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of k... | not-yet-due | |
| Reported results | 2021-001392-17 | A randomized, double-blind, cross-over, placebo-controlled, multi-center, Phase 2a study to assess the safety and efficacy of BAY 2395840 in patients with diabetic neuropathic pain Randomizované, d... | 2022-11-21 | due-trials |
| Reported results Terminated | 2021-001735-10 | COVID-19: A Phase 3, open-label, parallel group, multicenter clinical study to evaluate the safety, reactogenicity, and immunogenicity of the investigational SARS-CoV-2 mRNA vaccine CVnCoV in particip... | 2021-08-25 | due-trials |
| Trial is partly outside EEC | 2021-002071-19 | A 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of an age-and body weight adjusted oral finerenone regimen, in addition to an ACEI ... | bad-data | |
| Other | 2021-002905-89 | An 18-month, open-label, single-arm safety extension study of an age-and bodyweight-adjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children and young adults from... | not-yet-due | |
| Other | 2021-003037-11 | A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with ... | not-yet-due | |
| Reported results | 2021-003053-37 | A non-blinded retrospective biomarker add-on study to FIGARO-DKD for Bioprofiling the pharMacodynamic response to finerenone in FIGARO-DKD subjects (FIGARO-BM) Estudio de biomarcadores complementar... | 2021-12-31 | due-trials |
| Trial is outside EEC, and reported results | 2021-003537-11 | A Post Approval Commitment study to evaluate the efficacy, safety, and pharmacokinetics of KOVALTRY in Chinese children, adolescents/adults with severe hemophilia A. | bad-data | |
| Other | 2021-004858-30 | A phase 3, single group treatment, open-label, study to evaluate the safety of BAY 94-9027 infusions for prophylaxis and treatment of bleeding in previously treated children aged 7 to <12 years with s... | not-yet-due | |
| Trial is outside EEC | 2021-006191-16 | A multicenter, prospective, open-label, clinical study to assess the effect of using a new risk score approach to select the most appropriate prophylaxis regimen for reaching a favorable outcome, when... | bad-data | |
| Other | 2022-000095-18 | A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms caused by adjuvant endocrine therapy, over 5... | not-yet-due | |
| Completed, report not yet due | 2022-000520-38 | A randomized, placebo-controlled, double-blind, parallel-group, multicenter Phase 2a study to investigate efficacy and safety of zabedosertib (BAY 1834845) for the treatment of adult patients with mod... | 2024-02-28 | not-yet-due |
| Reported results Terminated | 2022-000690-73 | A Parallel-group Phase 4, Open-label, Two-arm Study to Assess the Safety and Efficacy of Intravitreal (IVT) Aflibercept with Proactive customized Treatment Intervals in Patients >/=50 Years of Age wit... | 2023-06-21 | due-trials |
| Other | 2022-000758-28 | A multicenter, international, randomized, active comparator-controlled, double-blind, double-dummy, parallel-group, 2-arm, Phase 3 study to compare the efficacy and safety of the oral FXIa inhibitor a... | not-yet-due | |
| Other | 2022-001067-27 | A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of isch... | not-yet-due | |
| Trial is outside EEC, and reported results | 2022-001504-17 | Prospective, historically controlled study to evaluate the efficacy and safety of a new pediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas’ disease | bad-data | |
| Trial is outside EEC, and reported results | 2022-003274-22 | A Randomized, Double-Blind, Single-Dose, Parallel, Placebo-Controlled Pivotal Trial to Confirm the Efficacy of a Fixed Dose Combination Tablet of Naproxen Sodium and Caffeine to Effectively Alleviate ... | bad-data |